Drug Trial Radar · NCT07614958
Phase 3 Clinical Study Evaluating Efficacy, Safety, and Tolerability of Obicetrapib Vs Bempedoic Acid to Treat Dyslipidemia in Adults With Primary Non-familial Hypercholesterolemia or Mixed Dyslipidemia at High to Very High Cardiovascular Risk, During a Treatment Period of Approximately 84 Days
Last checked: Nov 19, 2026Latest source record: Jun 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
426
Planned (sponsor's estimate)
Start
May 6, 2026
Primary completion
Jan 2027
Study completion Jan 2027
Sponsor
- Lead sponsor
- A. Menarini International Licensing S.A.Industry
- Sponsor type
- Industry
- Collaborators
- Medpace, Inc.
- First posted
- May 29, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase 3, randomized, double-blind, active-controlled study evaluates the efficacy and safety of obicetrapib (OBI) compared to bempedoic acid (BPA) in participants with dyslipidemia at high or very high cardiovascular risk. Participants must have elevated low density lipoprotein cholesterol (LDL-C) levels despite receiving maximally tolerated lipid lowering therapy. The primary objective is to compare the LDL-C lowering effect of OBI (a CETP inhibitor) against BPA at 12 weeks
Conditions
- Mixed Dyslipidemia
- Hypercholesterolaemia
Interventions
Obicetrapib 10 mg/Bempedoic Acid PlaceboDrug
Orally, Once Daily
Bempedoic Acid 180mg/Placebo ObicetrapibDrug
Orally, Once Daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- The primary efficacy endpoint is the percentage change from baseline to Day 84 in LDL-C in the OBI group compared to the BPA group.Time frame: 84 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
FutureMeds North Tees
Stockton-on-Tees, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.